$NRXP earnings report

NRx’s reported financial disclosure is limited to six-month loss figures and balance-sheet cash, rather than a complete standalone second-quarter income statement. Net loss for the six months ended June 30, 2026 was $18.0 million, versus $23.1 million during the comparable 2025 period. The company attributed the change primarily to fair-value accounting measurements and other non-recurring charges associated with conversion and restructuring of previously issued convertible notes in the 2025 period. At the same time, net operating loss increased to $11.3 million from $7.6 million, driven by research and development costs related to acquired assets and higher selling, general and administrative costs, including commercial-launch preparation.

Liquidity was the central financial positive in the release. Cash and cash equivalents were approximately $26.7 million as of June 30, 2026, compared with $7.8 million as of December 31, 2025. The company linked the increase principally to its public common-stock offering, described as generating $22.3 million of gross proceeds. Management stated that current cash resources, anticipated clinic-revenue growth, and opportunistic use of its active at-the-market facility would support operations for at least one year.

Operationally, the main near-term event is the preservative-free ketamine ANDA. The company said FDA identified no major deficiencies related to the drug or its manufacture, while identifying a single major deficiency concerning a manufacturer’s attestation for the vial’s luer lock component. NRx said it submitted that attestation and is building five million units of launch stock, with anticipated post-launch manufacture of 1 million units per month. The company aims for 2026 approval and commercialization, but the release also states that it has not predicted the outcome of future regulatory determinations.

The company also outlined pipeline and commercial-network activity. DARPA selected NRx as prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of NRX-101 with robotic TMS, with anticipated non-dilutive funding exceeding $11.5 million subject to contracting. NRx is also advancing the NRX-100 NDA using Real World Evidence from more than 65,000 patients and is aiming for 2027 approval. HOPE Therapeutics expanded into Sarasota and Boca Raton and began treating patients with Zeta Surgical’s FDA-cleared TMS navigation system.

The release contains no reported revenue, segment revenue, gross margin, EPS, operating cash flow, free cash flow, debt balance, or prior-quarter financial line items. As a result, the financial read depends principally on the cash increase, the six-month loss trends, and execution against regulatory, manufacturing, contracting, and clinic-growth objectives. There was no prior outlook supplied for comparison, and the filing does not provide a basis to assess performance against prior guidance.